Alkeus Launches Phase 3 Stargardt Trial
-
By
-
Carlos Quezada Ruiz, MD
-
July 15, 2026
-
2 min
Clinical Report: Alkeus Launches Phase 3 Stargardt Trial
Overview
Alkeus Pharmaceuticals has initiated the global phase 3 NORTHSTAR trial to evaluate gildeuretinol for Stargardt disease. This trial aims to enroll approximately 230 patients and assess the treatment's effects on retinal atrophic lesions and low-luminance visual acuity over a 24-month period.
Background
Stargardt disease is a genetic retinal disorder that leads to vision loss and currently lacks an approved disease-modifying therapy. The NORTHSTAR trial is designed to evaluate gildeuretinol, which has been studied in earlier trials.
Data Highlights
No numerical data available in the source material.
Key Findings
- The NORTHSTAR trial is a global, randomized, double-masked, placebo-controlled study.
- Approximately 230 patients will be enrolled, randomized 1:1 to receive either placebo or gildeuretinol.
- The primary endpoint is the change in the rate of growth of retinal atrophic lesions from month 6 to month 24.
- A key secondary endpoint is the change from baseline in low-luminance visual acuity.
- Positive results were previously observed in the TEASE-2 trial for low-luminance visual acuity.
- Gildeuretinol has shown benefits in a geographic atrophy program, indicating its potential efficacy across related retinal diseases.
Clinical Implications
The NORTHSTAR trial may provide data on the efficacy of gildeuretinol in managing Stargardt disease.
Conclusion
The launch of the NORTHSTAR trial is an important development in the search for therapies for Stargardt disease.
Related Resources & Content
- Alkeus Pharmaceuticals, Inc., Alkeus Pharmaceuticals Announces First Patient Dosed in Pivotal Global Phase 3 NORTHSTAR Study of Oral Gildeuretinol in Stargardt Disease, 2026 -- Alkeus Pharmaceuticals Announces First Patient Dosed in Pivotal Global Phase 3 NORTHSTAR Study of Oral Gildeuretinol in Stargardt Disease
- Retinal Physician, Phase 3 Study of Gildeuretinol Begins, 2026 -- Phase 3 Study of Gildeuretinol Begins
- Ophthalmology Management, First Patient Dosed in Oral Gildeuretinol Stargardt Disease Phase 3 Study, 2026 -- First Patient Dosed in Oral Gildeuretinol Stargardt Disease Phase 3 Study
- Optometric Management, First Patient Dosed in Oral Gildeuretinol Stargardt Disease Phase 3 Study, 2026 -- First Patient Dosed in Oral Gildeuretinol Stargardt Disease Phase 3 Study
- Retinal Physician — Oral Gildeuretinol Slows Stargardt Progression
- Update on the Management of ABCA4 Retinopathy (Stargardt Disease)
- EURETINA IRD Consensus Supplement
- Alkeus Pharmaceuticals, Inc. » Alkeus Pharmaceuticals Announces First Patient Dosed in Pivotal Global Phase 3 NORTHSTAR Study of Oral Gildeuretinol in Stargardt Disease
- Study Details | NCT07419334 | Study of ALK-001 on the Progression of Stargardt Disease | ClinicalTrials.gov
- Alkeus Pharmaceuticals, Inc. » Alkeus Pharmaceuticals Announces Two Presentations of Oral Gildeuretinol Data During the 48th Annual Meeting of the Macula Society Being Held February 12-15, 2025
- Alkeus Pharmaceuticals, Inc. » Alkeus Pharmaceuticals Announces Presentation of Positive Interim TEASE-3 Study Data in Early-Stage Stargardt Disease Patients Treated with Oral Gildeuretinol
- Microsoft Word - Alkeus ASRS TEASE-3 update press release_08072025_final
- Potential Oral Stargardt Treatment Advances to Phase 3 Clinical Trial — Foundation Fighting Blindness
- New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease | Belite Bio, Inc.
- Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease | Belite Bio, Inc.
- Belite Bio Reports Third Quarter 2025 Financial Results and Provides a Corporate Update | Belite Bio, Inc.
- SpliceBio Initiates Dose-Expansion Portion of Phase 1/2 ASTRA Clinical Trial for SB-007, a Dual-AAV Gene Therapy for Stargardt Disease
- Study Details | NCT06942572 | A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1) | ClinicalTrials.gov
- SpliceBio Initiates Dose-Expansion Portion of Phase 1/2 ASTRA Clinical Trial for SB-007,
- Ascidian Completes Dose Escalation Portion of Phase 1/2 STELLAR Trial of ACDN-01 for Stargardt Disease and Announces Expanded Clinical Study Plans
- Study Details | NCT06467344 | Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR) | ClinicalTrials.gov
- Study Details | NCT07161544 | A Study of AAVB-039 in Participants With Stargardt Disease (STGD1) | ClinicalTrials.gov
- AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease - News - AAVantgarde
- Study Details | NCT06591806 | An Observational Study in Children and Adults With Stargardt Disease | ClinicalTrials.gov
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
